Citizens Initiates Coverage On Faeth Therapeutics with Market Outperform Rating, Announces Price Target of $51
Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. FTH | 0.00 |
Citizens analyst Silvan Turkcan initiates coverage on Faeth Therapeutics (NASDAQ:
FTH) with a Market Outperform rating and announces Price Target of $51.
